Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001753926-26-000097
- form_type
- 8-K
- ticker
- PTHS
- cik
- 0001919246
- company_name
- Pelthos Therapeutics Inc.
- filed_at
- 2026-01-13T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:36.756701+00:00
- generated_at
- 2026-05-16T10:43:17.076791+00:00
- sec_items
- ["1.01", "2.03", "3.02", "7.01", "9.01"]
- event_type
- debt
- sentiment
- neutral
- materiality_score
- 0.65
- calibrated_materiality_score
- 0.65
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001753926-26-000097
- json_url
- https://secwatch.observer/filing/0001753926-26-000097.json
- markdown_url
- https://secwatch.observer/filing/0001753926-26-000097.md
- text_url
- https://secwatch.observer/filing/0001753926-26-000097.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1919246/000175392626000097/0001753926-26-000097-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1919246/000175392626000097/g085079_8k.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
EMAT
EMAT secures $100M convertible debenture facility from Yorkville; first $20M tranche issued
Evolution Metals & Technologies Corp.
May 11, 2026, 7:59 PM ET
debt
Items 1.01, 2.03, 3.02, 7.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 2.03, 3.02, 7.01, 9.01
same event type: debt
similar materiality
This filing
On January 12, 2026 (the “ Closing Date ”), Pelthos Therapeutics Inc., a Nevada corporation (the “ Company ”), LNHC, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“ LNHC ”) and Channel Pharmaceutical Corporation, a Nevada corporation and a wholly subsidiary of the Company (“ Channel ”), as co-borrowers (together with the Company, the “ Borrowers ”), entered into a Venture Loan and Security Agreement (the “ Loan Agreement ”) by and among the Borrowers and Horizon Technology Finance Corporation, a Delaware corporation, as lender and collateral agent (the “ Lender ”).
Comparable filing
On May 7, 2026, Evolution Metals & Technologies Corp. (“EMAT” or the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with YA II PN, LTD. (“Yorkville”), a fund managed by Yorkville Advisors Global, LP, pursuant to which the Company agreed to issue and sell to Yorkville convertible debentures in the aggregate principal amount of up to $100,000,000
Filing page
SEC filing
TBH
Brag House issues $2.5M convertible notes at 25% OID; proceeds for House of Doge merger
Brag House Holdings, Inc.
May 8, 2026, 7:59 PM ET
debt
Items 1.01, 2.03, 3.02, 9.01
same fact type: material_agreement
same SEC item: 1.01, 2.03, 3.02, 9.01
same event type: debt
similar materiality
This filing
On January 12, 2026 (the “ Closing Date ”), Pelthos Therapeutics Inc., a Nevada corporation (the “ Company ”), LNHC, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“ LNHC ”) and Channel Pharmaceutical Corporation, a Nevada corporation and a wholly subsidiary of the Company (“ Channel ”), as co-borrowers (together with the Company, the “ Borrowers ”), entered into a Venture Loan and Security Agreement (the “ Loan Agreement ”) by and among the Borrowers and Horizon Technology Finance Corporation, a Delaware corporation, as lender and collateral agent (the “ Lender ”).
Comparable filing
In connection with the Offering, on May 4, 2026, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with the Purchasers.
Filing page
SEC filing
KNX
Knight-Swift closes $1.5B convertible note offering at 1.00% due 2031; proceeds used to repay term loans and revolver
Knight-Swift Transportation Holdings Inc.
May 8, 2026, 7:59 PM ET
debt
Items 1.01, 2.03, 3.02, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 2.03, 3.02, 9.01
same event type: debt
similar materiality
This filing
On January 12, 2026 (the “ Closing Date ”), Pelthos Therapeutics Inc., a Nevada corporation (the “ Company ”), LNHC, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“ LNHC ”) and Channel Pharmaceutical Corporation, a Nevada corporation and a wholly subsidiary of the Company (“ Channel ”), as co-borrowers (together with the Company, the “ Borrowers ”), entered into a Venture Loan and Security Agreement (the “ Loan Agreement ”) by and among the Borrowers and Horizon Technology Finance Corporation, a Delaware corporation, as lender and collateral agent (the “ Lender ”).
Comparable filing
On May 8, 2026, Knight-Swift Transportation Holdings Inc. (the "Company") completed its previously announced private offering (the "Offering") of $1.5 billion aggregate principal amount of 1.00% Convertible Senior Notes due 2031 (the "Notes"), including the exercise in full of the initial purchasers' option to purchase up to an additional $200.0 million principal amount of the Notes.
Filing page
SEC filing
OCGN
Ocugen completes $115M convertible note offering at 6.75%, repays Avenue loan
Ocugen, Inc.
May 7, 2026, 7:59 PM ET
debt
Items 1.01, 1.02, 2.02, 2.03, 3.02, 9.01
same fact type: material_agreement
same SEC item: 1.01, 2.03, 3.02, 9.01
same event type: debt
similar materiality
This filing
On January 12, 2026 (the “ Closing Date ”), Pelthos Therapeutics Inc., a Nevada corporation (the “ Company ”), LNHC, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“ LNHC ”) and Channel Pharmaceutical Corporation, a Nevada corporation and a wholly subsidiary of the Company (“ Channel ”), as co-borrowers (together with the Company, the “ Borrowers ”), entered into a Venture Loan and Security Agreement (the “ Loan Agreement ”) by and among the Borrowers and Horizon Technology Finance Corporation, a Delaware corporation, as lender and collateral agent (the “ Lender ”).
Comparable filing
On May 7, 2026, Ocugen, Inc. (the “Company”) completed its previously announced private offering (the “offering”) of $115.0 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034 (the “notes”). The notes were issued pursuant to an indenture, dated May 7, 2026 (the “Indenture”), between the Company and U.S. Bank Trust Company, National Association, as trustee.
Filing page
SEC filing
RNST
Renasant prices $300M 6.25% sub notes due 2036, net $295.7M, may redeem $40M 5.50% notes
RENASANT CORP
May 7, 2026, 7:59 PM ET
debt
Items 1.01, 2.03, 7.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 2.03, 7.01, 9.01
same event type: debt
similar materiality
This filing
On January 12, 2026 (the “ Closing Date ”), Pelthos Therapeutics Inc., a Nevada corporation (the “ Company ”), LNHC, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“ LNHC ”) and Channel Pharmaceutical Corporation, a Nevada corporation and a wholly subsidiary of the Company (“ Channel ”), as co-borrowers (together with the Company, the “ Borrowers ”), entered into a Venture Loan and Security Agreement (the “ Loan Agreement ”) by and among the Borrowers and Horizon Technology Finance Corporation, a Delaware corporation, as lender and collateral agent (the “ Lender ”).
Comparable filing
On May 4, 2026, Renasant Corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Keefe, Bruyette & Woods, Inc. and Stephens Inc., as representatives of the underwriters listed on Schedule I to the Underwriting Agreement, for the issuance and sale of $300 million aggregate principal amount of its 6.25% Fixed-to-Floating Rate Subordinated Notes due 2036
Filing page
SEC filing
LIQT
LiqTech to convert $3M of $6M debt to equity, pay $3M cash in restructuring
LIQTECH INTERNATIONAL INC
June 1, 2026, 5:17 PM ET
debt
Items 1.01, 3.02, 9.01
same fact type: material_agreement
same SEC item: 1.01, 3.02, 9.01
same event type: debt
similar materiality
This filing
On January 12, 2026 (the “ Closing Date ”), Pelthos Therapeutics Inc., a Nevada corporation (the “ Company ”), LNHC, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“ LNHC ”) and Channel Pharmaceutical Corporation, a Nevada corporation and a wholly subsidiary of the Company (“ Channel ”), as co-borrowers (together with the Company, the “ Borrowers ”), entered into a Venture Loan and Security Agreement (the “ Loan Agreement ”) by and among the Borrowers and Horizon Technology Finance Corporation, a Delaware corporation, as lender and collateral agent (the “ Lender ”).
Comparable filing
On May 26, 2026, LiqTech International, Inc. (the “Company”) entered into a Debt Cancellation Agreement (the “Debt Cancellation Agreement”) with affiliates of Bleichroeder L.P., 21 April Fund, L.P., and 21 April Fund, Ltd. (the “Note Holders”).
Filing page
SEC filing
TCPC
BlackRock TCP Capital closes $535.8M CLO securitization, repays existing debt facilities
BlackRock TCP Capital Corp.
June 1, 2026, 4:50 PM ET
debt
Items 1.01, 1.02, 2.03, 9.01
same fact type: material_agreement
same SEC item: 1.01, 2.03, 9.01
same event type: debt
similar materiality
This filing
On January 12, 2026 (the “ Closing Date ”), Pelthos Therapeutics Inc., a Nevada corporation (the “ Company ”), LNHC, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“ LNHC ”) and Channel Pharmaceutical Corporation, a Nevada corporation and a wholly subsidiary of the Company (“ Channel ”), as co-borrowers (together with the Company, the “ Borrowers ”), entered into a Venture Loan and Security Agreement (the “ Loan Agreement ”) by and among the Borrowers and Horizon Technology Finance Corporation, a Delaware corporation, as lender and collateral agent (the “ Lender ”).
Comparable filing
On the Closing Date, TCPC II entered into a payoff letter (“ Payoff Letter ”) to terminate the Loan and Servicing Agreement dated as of August 4, 2020 (as amended, modified, supplemented, restated or replaced from time to time, the “ LSA ”) among TCPC II, as borrower, Special Value Continuation Partners LLC, as servicer, Morgan Stanley Asset Funding Inc., as administrative agent and Morgan Stanley Bank, N.A., City National Bank, as lenders and Wells Fargo Bank, National Association, as the collateral agent, the account bank and the collateral custodian.
Filing page
SEC filing
BFAM
Bright Horizons secures $375M term loan, ups revolver to $1B with 2030 maturity
BRIGHT HORIZONS FAMILY SOLUTIONS INC.
June 1, 2026, 4:31 PM ET
debt
Items 1.01, 2.03, 9.01
same fact type: material_agreement
same SEC item: 1.01, 2.03, 9.01
same event type: debt
similar materiality
This filing
On January 12, 2026 (the “ Closing Date ”), Pelthos Therapeutics Inc., a Nevada corporation (the “ Company ”), LNHC, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“ LNHC ”) and Channel Pharmaceutical Corporation, a Nevada corporation and a wholly subsidiary of the Company (“ Channel ”), as co-borrowers (together with the Company, the “ Borrowers ”), entered into a Venture Loan and Security Agreement (the “ Loan Agreement ”) by and among the Borrowers and Horizon Technology Finance Corporation, a Delaware corporation, as lender and collateral agent (the “ Lender ”).
Comparable filing
On June 1, 2026 (the “ Closing Date ”), Bright Horizons Family Solutions LLC (the “ Borrower ”), a wholly-owned indirect subsidiary of Bright Horizons Family Solutions Inc. (the “ Company ”), entered into the Fifth Amendment to Second Amended and Restated Credit Agreement
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.